Role of the Kaiso gene in the development of inflammation in Mucin-2 defcient mice
E. A. Litvinova,
K. M. Achasova,
M. A. Borisova,
S. V. Zhenilo,
E. B. Prokhortchouk,
E. N. Kozhevnikova https://doi.org/10.18699/VJ18.453
Abstract
The number of people with inflammatory bowel disease (IBD) is constantly increasing worldwide. The main factors that have effects on the etiology of the disease are genetic, environmental and immunological. However, the mechanism of disease development and effective treatment of IBD have not yet been found. Animal models help address these problems. The most popular model is considered to be transgenic models in which individual genes are knocked out. One of such models for the study of IBD are mice with a null mutation of the Muc2 gene encoding the Mucin-2 protein, which is involved in the formation of a protective mucin layer in the small and large intestine. Some of transcription factors that change the expression of intestinal genes are involved in the development of IBD and colorectal cancer. One of such transcription factors is “zinc fnger” domain-containing protein Kaiso which is able to bind to methylated DNA. In this study, we assessed the role of Kaiso in the development of intestinal inflammation using the experimental model of C57BL/6Muc2-/-Kaiso-/-. We have shown that mice with impaired intestinal barrier function that develop processes similar to human IBD also develop inflammatory responses, such as increased expression of Il1, Tnf and Il17a genes. The defciency of the Kaiso transcription factor in Mucin-2 knockout mice causes a decrease in the expression level of only the Cox2 and Tff3 genes. Perhaps a decline in the expression of the gene encoding cyclooxygenase-2 can lead to a decrease in the expression of the antibacterial factor Trefoil factor 3. However, in the experimental model of IBD, Kaiso protein did not play a signifcant role in the regulation of pro-inflammatory cytokines of tumor necrosis factor and interleukins 1 and 17.
About the Authors
E. A. Litvinova
Institute of Cytology and Genetics, SB RAS
Russian Federation
Novosibirsk
Russian Federation
Novosibirsk
K. M. Achasova
Institute of Cytology and Genetics, SB RAS
Russian Federation
Novosibirsk
Russian Federation
Novosibirsk
M. A. Borisova
Institute of Cytology and Genetics, SB RAS
Russian Federation
Novosibirsk
Russian Federation
Novosibirsk
S. V. Zhenilo
Federal Research Centre “Fundamentals of Biotechnology”, RAS, Institute of Bioengineering
Russian Federation
Moscow
Russian Federation
Moscow
E. B. Prokhortchouk
Federal Research Centre “Fundamentals of Biotechnology”, RAS, Institute of Bioengineering
Russian Federation
Moscow
Russian Federation
Moscow
E. N. Kozhevnikova
Institute of Cytology and Genetics, SB RAS
Russian Federation
Novosibirsk
Russian Federation
Novosibirsk
References
1. Benchimol E.I., Fortinsky K.J., Gozdyra P., Van den Heuvel M., Van Limbergen J., Griffths A.M. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends. Inflamm. Bowel Dis. 2011;17(1):423-439. DOI 10.1002/ibd.21349.
2. Bergstrom K.S.B., Kissoon-Singh V., Gibson D.L., Ma C., Montero M., Sham H.P., Vallance B.A. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog. 2010;6(5):e1000902. DOI 10.1371/journal.ppat.1000902.
3. Burger-van Paassen N., van der Sluis M., Bouma J., Korteland-van Male A.M., Lu P., Van Seuningen I., Boehm G., van Goudoever J.B., Renes I.B. Colitis development during the suckling-weaning transition in mucin Muc2-defcient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2011;301(4):G667-G678. DOI 10.1152/ajpgi.00199.2010.
4. Caprioli F., Marafni I., Facciotti F., Pallone F., Monteleone G. Th17 immune response in IBD: A new pathogenic mechanism. J. Crohns Colitis. 2008;2(4):291-295. DOI 10.1016/j.crohns.2008.05.004.
5. Cross R.K., Wilson K.T. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 2003;9(3):179-189. DOI 10.1097/00054725-200305000-00006.
6. Foltz C.J., Fox J.G., Cahill R., Murphy J.C., Yan L., Shames B., Schauer D.B. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter. 1998;3(2):69-78.
7. Guihot G., Guimbaud R., Bertrand V., Narcy-Lambare B., Couturier D., Duée P.H., Chaussade S., Blachier F. Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn’s disease. Amino Acids. 2000;18(3):229-237.
8. Holleran G., Lopetuso L., Petito V., Graziani C., Ianiro G., McNamara D., Gasbarrini A., Scaldaferri F. The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease. Int. J. Mol. Sci. 2017;18(10):E2020. DOI 10.3390/ijms18102020.
9. Kopp Z.A., Jain U., Limbergen J.V., Stadnyk A.W. Do antimicrobial peptides and complement collaborate in the intestinal mucosa? Front. Immunol. 2015;6:17. DOI 10.3389/fmmu.2015.00017.
10. Lopes E.C., Valls E., Figueroa M.E., Mazur A., Meng F.G., Chiosis G., Laird P.W., Schreiber-Agus N., Greally J.M., Prokhortchouk E., Melnick A. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Res. 2008;68(18):7258-7263. DOI 10.1158/0008-5472.CAN-08-0344.
11. Mähler (Convenor) M., Berard M., Feinstein R., Gallagher A., IllgenWilcke B., Pritchett-Corning K., Raspa M. FELASA recommendations for the health monitoring of mouse, rat, hamster, guineapig and rabbit colonies in breeding and experimental units. Lab. Anim. 2014; 48:178-192. DOI 10.1177/0023677213516312.
12. Martens E.C., Koropatkin N.M., Smith T.J., Gordon J.I. Complex glycan catabolism by the human gut microbiota: The bacteroidetes Sus-like paradigm. J. Biol. Chem. 2009;284(37):24673-24677. DOI 10.1074/jbc.R109.022848.
13. Morgan X.C., Tickle T.L., Sokol H., Gevers D., Devaney K.L., Ward D.V., Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79. DOI 10.1186/gb-2012-13-9-r79.
14. O’Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., Kolls J.K., Flavell R.A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 2009;10:603-610. DOI 10.1038/ni.1736.
15. Parisi A., Lacour F., Giordani L., Colnot S., Maire P., Le Grand F. APC is required for muscle stem cell proliferation and skeletal muscle tissue repair. J. Cell Biol. 2015;210(5):717-726. DOI 10.1083/jcb. 201501053.
16. Podolsky D.K., Lynch-Devaney K., Stow J.L., Oates P., Murgue B., DeBeaumont M., Sands B.E., Mahida Y.R. Identifcation of human intestinal trefoil factor. Goblet cell-specifc expression of a peptide targeted for apical secretion. J. Biol. Chem. 1993;268(9):6694- 6702.
17. Prokhortchouk A., Hendrich B., Jørgensen H., Ruzov A., Wilm M., Georgiev G., Bird A., Prokhortchouk E. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev. 2001;15(13):1613-1618. DOI 10.1101/gad.198501.
18. Shattuck-Brandt R.L., Varilek G.W., Radhika A., Yang F., Washington M.K., Dubois R.N. Cyclooxygenase-2 expression is increased in the subepithelial myofbroblasts of colon and cecal carcinomas from IL-10 (-/-) mice. Gastroenterology. 2000;118:337-345.
19. Shi L., Zhou P.-H., Xi J.-L., Yu H.-G., Zhang B-H. Recombinant human Trefoil factor 3 ameliorates bowel injury: its anti-inflammatory effect on experimental necrotizing enterocolitis. Int. J. Pept. 2014; 2014:634135. DOI 10.1155/2014/634135.
20. Singer I.I., Kawka D.W., Schloemann S., Tessner T., Riehl T., Stenson W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998;115:297-306.
21. Strober W., Zhang F., Kitani A., Fuss I., Fichtner-Feigl S. Proinflammatory cytokines underlying the inflammation of Crohn’s disease. Curr. Opin. Gastroenterol. 2010;26(4):310-317. DOI 10.1097/MOG. 0b013e328339d099.
22. Taupin D., Podolsky D.K. Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell Biol. 2003;4(9):721-732. DOI 10.1038/nrm1203.
23. Vermeulen J.F., van de Ven R.A., Ercan C., van der Groep P., van der Wall E., Bult P., Christgen M., Lehmann U., Daniel J., van Diest P.J., Derksen P.W.B. Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer. PLoS One. 2012;7: e37864. DOI 10.1371/journal.pone.0037864.
24. Wang D., Dubois R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29(6):781-788. DOI 10.1038/onc.2009.421.
25. Wang H., Liu W., Black S., Turner O., Daniel J.M., Dean-Colomb W., He Q.P., Davis M., Yates C. Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. Oncotarget. 2016;7(5):5677-5689. DOI 10.18632/oncotarget.6801.
26. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., Wang Y.H., Schluns K.S., Broaddus R.R., Zhu Zh., Dong Ch. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 2008; 205(5):1063-1075. DOI 10.1084/jem.20071978.
Review
Views:
903
Email this article 